{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:10:11Z","timestamp":1790975411068,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108803","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:02:40Z","timestamp":1761354160000},"page":"108803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-7538","authenticated-orcid":false,"given":"Martin","family":"Faehling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Fallscheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schmiederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Str\u00e4ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Seifarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108803_b0005","unstructured":"World Cancer Research Fund International. Lung cancer statistics; 2020. https:\/\/www.wcrf.org\/cancer-trends\/lung-cancer-statistics\/. Accessed 6 April 2024. n.d."},{"key":"10.1016\/j.lungcan.2025.108803_b0010","unstructured":"WHO. Lung Cancer: Key Facts; 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer#:\u223c:text=GLOBOCAN%202020%20estimates%20of%20cancer,deaths%20(18%25)%20in%202020. Accessed 6 April 2024 n.d."},{"key":"10.1016\/j.lungcan.2025.108803_b0015","unstructured":"Cancer.net. Lung Cancer - Non-Small Cell. https:\/\/www.cancer.net\/cancer-t\u00fdpes\/lung-cancer-non-small-cell\/statistics. Accessed 6 April 2024. n.d."},{"key":"10.1016\/j.lungcan.2025.108803_b0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann. Glob. Health"},{"key":"10.1016\/j.lungcan.2025.108803_b0025","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1164\/rccm.201702-0433CI","article-title":"AJRCCM: 100-year anniversary. the shifting landscape for lung cancer: past, present, and future","volume":"195","author":"Vachani","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2025.108803_b0030","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108803_b0035","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2025.108803_b0040","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/j.lungcan.2004.07.967","article-title":"Treatment of brain metastases from lung cancer: chemotherapy","volume":"45","author":"Schuette","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0045","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108803_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1212788","article-title":"Genomic profiling and sites of metastasis in non-small cell lung cancer","volume":"13","author":"Chan","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108803_b0055","article-title":"Genomic landscape and actionable mutations of brain metastases derived from non\u2013small cell lung cancer: a systematic review","volume":"5","author":"Andrews","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.lungcan.2025.108803_b0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108803_b0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9016","article-title":"Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)","volume":"41","author":"Dingemans","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2025.108803_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2021.02.005","article-title":"KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)","volume":"154","author":"Sebastian","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0075","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1078-0432.CCR-22-0383","article-title":"Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer","volume":"28","author":"Sabari","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108803_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2021.05.026","article-title":"A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease","volume":"159","author":"Spira","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113911","article-title":"Sotorasib in KRAS G12C-mutated non-small cell lung cancer: a multicenter real-world experience from the compassionate use program in Germany","volume":"201","author":"Stratmann","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103473","article-title":"Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort","volume":"9","author":"Thomas","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2025.108803_b0095","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/ijms17122132","article-title":"EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer","volume":"17","author":"Tomasini","year":"2016","journal-title":"IJMS"},{"issue":"23","key":"10.1016\/j.lungcan.2025.108803_b0100","first-page":"02423","article-title":"Outcome of first-line treatment with pembrolizumab according to KRAS\/TP53 mutational status for nonsquamous programmed death-ligand 1-high (\u226550%) NSCLC in the German national network genomic medicine lung cancer","volume":"S1556\u20130864","author":"Bischoff","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108803_b0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR -mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108803_b0110","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in previously untreated EGFR-mutated advanced NSCLC","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108803_b0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0120","doi-asserted-by":"crossref","first-page":"56998","DOI":"10.18632\/oncotarget.10933","article-title":"A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?","volume":"7","author":"Han","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2025.108803_b0125","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-024-02799-9","article-title":"Clinical Management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: a systematic literature review","author":"Khasraw","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.lungcan.2025.108803_b0130","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3390\/cancers17071237","article-title":"Trends in overall survival in lung adenocarcinoma with EFGR Mutation, KRAS mutation, or no mutation","volume":"17","author":"Faehling","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108803_b0135","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108803_b0140","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/0284186X.2017.1328128","article-title":"Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study","volume":"56","author":"Hsu","year":"2017","journal-title":"Acta Oncol."},{"key":"10.1016\/j.lungcan.2025.108803_b0145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2013.07.023","article-title":"Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors","volume":"82","author":"Griffioen","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non\u2013small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0155","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/cancers13081893","article-title":"Management of synchronous extrathoracic oligometastatic non-small cell lung cancer","volume":"13","author":"Jones","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108803_b0160","article-title":"A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers","volume":"199","author":"Zerdes","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0165","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41598-024-56046-w","article-title":"Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases","volume":"14","author":"Kahraman","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2025.108803_b0170","doi-asserted-by":"crossref","first-page":"e7208","DOI":"10.1002\/cam4.7208","article-title":"Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21\u2013L858R mutations: a real-world study","volume":"13","author":"Liang","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2025.108803_b0175","article-title":"Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer","volume":"10","author":"Batra","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.lungcan.2025.108803_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100161","article-title":"Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer","volume":"6","author":"El Shafie","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2025.108803_b0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2020.08.007","article-title":"Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing","volume":"148","author":"Christopoulos","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0190","article-title":"Distinct progression and efficacy of first-line osimertinib treatment according to mutation subtypes in metastatic NSCLC harboring EGFR mutations","volume":"5","author":"Takeyasu","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2025.108803_b0195","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108803_b0200","doi-asserted-by":"crossref","unstructured":"Balasubramanian SK, Sharma M, Venur VA, Schmitt P, Kotecha R, Chao ST, et al. Impact of EGFR mutation and ALK rearrangement on the outcomes of non\u2013small cell lung cancer patients with brain metastasis. Neuro-Oncology 2019:noz155. https:\/\/doi.org\/10.1093\/neuonc\/noz155.","DOI":"10.1093\/neuonc\/noz155"},{"key":"10.1016\/j.lungcan.2025.108803_b0205","first-page":"200","article-title":"Efficacy of tyrosine kinase inhibitors in ALK and EGFR-mutated non-small cell lung cancer with brain metastases","volume":"13","author":"Shalata","year":"2025","journal-title":"Med. Sci."},{"key":"10.1016\/j.lungcan.2025.108803_b0210","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108803_b0215","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaoncol.2024.2640","article-title":"Lazertinib in EGFR-variant non-small cell lung cancer with CNS failure to prior EGFR tyrosine kinase inhibitors: a nonrandomized controlled trial","volume":"10","author":"Hong","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108803_b0220","doi-asserted-by":"crossref","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, Yang JC-H, Liu Y, Valdiviezo N, et al. Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC. N Engl J Med 2025:NEJMoa2510308. https:\/\/doi.org\/10.1056\/NEJMoa2510308.","DOI":"10.1056\/NEJMoa2510308"},{"key":"10.1016\/j.lungcan.2025.108803_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108683","article-title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial","volume":"207","author":"Dingemans","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108803_b0230","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRASG12C -mutated non\u2013small-cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2025.108803_b0235","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO-25-00040","article-title":"Single-agent divarasib in patients with KRAS G12C-positive non-small cell lung cancer: long-term follow-up of a phase i study","volume":"43","author":"Sacher","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:44:46Z","timestamp":1762490686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S0169500225006956"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108803","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108803"}}